1. Home
  2. News
  3. Mesoblast Limited
  4. ODAC Votes in Favor of Remestemcel-L for GvHD
More Mesoblast Limited news
Mesoblast LimitedASX: MSB

ODAC Votes in Favor of Remestemcel-L for GvHD

Aug 14, 2020 at 12:12 AM EDT · Issued by Mesoblast Limited

Filed with ASX · Aug 14, 2020 at 12:12 AM EDT · 3 pages · English

On 6ix: 6ix.com/news/odac-votes-in-favor-of-remestemcel-l-for-gvhd

Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26↗

Mesoblast Limited on 6ix

Story so far

  • COVID-19/GVHD Update, Quarterly Report and Appendix 4CJul 30, 2020
  • FDA Advisory Committee Sets Review Date for Remestemcel-LJul 21, 2020
  • Remestemcel-L Improves Outcomes in Inflammatory Lung DiseaseJun 1, 2020

Earlier from Mesoblast

  • Update on Scheduled FDA Advisory Committee MeetingAug 11, 2020
  • COVID-19/GVHD Update, Quarterly Report and Appendix 4CJul 30, 2020
  • FDA Advisory Committee Sets Review Date for Remestemcel-LJul 20, 2020
  • S&P DJI Announces June 2020 Quarterly RebalanceJun 11, 2020
  • Remestemcel-L Improves Outcomes in Inflammatory Lung DiseaseJun 1, 2020

Later from Mesoblast

  • DSMB Recommends Continuation of Phase 3 COVID-19 TrialSep 4, 2020
  • MSB Wins Fierce Biotech Innovation Award for Remestemcel-LSep 15, 2020
  • COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4COct 28, 2020
  • DSMB Analysis Recommends to Continue P3 COVID-19 ARDS TrialNov 10, 2020
  • First Quarter Results PresentationNov 19, 2020
All Mesoblast news releases↗

Follow Mesoblast into a list and get an email when it puts out news.

Follow Mesoblast
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer